5-(N-benzyloxycarbonyl-D-phenylalaninamidomethyl)-3-bromo-4,5-dihydroisoxazole | 744198-15-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5-(N-benzyloxycarbonyl-D-phenylalaninamidomethyl)-3-bromo-4,5-dihydroisoxazole
• 英文别名: carbamic acid, [(1R)-2-[[(3-bromo-4,5-dihydro-5-isoxazolyl)methyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester；benzyl N-[(2R)-1-[(3-bromo-4,5-dihydro-1,2-oxazol-5-yl)methylamino]-1-oxo-3-phenylpropan-2-yl]carbamate
• CAS: 744198-15-0
• 化学式: C₂₁H₂₂BrN₃O₄
• 分子量: 460.327
• InChiKey: FGARZQSJAHGKBO-QRWMCTBCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  89
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Medical Devices and Coatings Therefor
  申请人：Lambert Peter A.

  公开号：US20080299170A1

  公开（公告）日：2008-12-04

  A coating for a medical device, the device generally being of the type which is to be used internally in a subject, includes a transglutaminase (TGase) inhibitor. The Tgase inhibitor effectively prevents the activity of any Tgase involved in clot formation or clot stability. Preferably, the transglutaminase inhibitor is a factor XIIIa inhibitor. The coating may be prepared by suitable processes such as esterification. The coating may be immobilized on a suitable medical device in a number of ways and is preferably included in a TGase inhibitor containing polymer. The coating may also include a suitable antimicrobial agent.

  一种医疗设备的涂层，该设备通常是用于在体内使用的类型，包括一种转谷氨酰胺酶（TGase）抑制剂。TGase抑制剂有效地防止了任何参与凝血形成或凝血稳定的TGase的活性。最好的情况是，转谷氨酰胺酶抑制剂是因子XIIIa抑制剂。该涂层可以通过适当的过程（如酯化）制备。涂层可以以多种方式固定在适当的医疗设备上，最好包含在含有TGase抑制剂的聚合物中。涂层还可以包括适当的抗微生物剂。
• Transglutaminase inhibitors and methods of use thereof
  申请人：Khosla Chaitan

  公开号：US20060052308A1

  公开（公告）日：2006-03-09

  Transglutaminase inhibitors and methods of use thereof are provided.

  本发明提供了谷氨酰胺酰转移酶抑制剂及其使用方法。
• Drug therapy for Celiac Sprue
  申请人：——

  公开号：US20040167069A1

  公开（公告）日：2004-08-26

  Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.

  给予具有有效剂量的tTGase抑制剂给具有乳糜泻或疱疹性荨麻疹的患者可以减少毒性麸质寡肽的毒性效应，从而减轻或消除麸质的损害作用。
• DRUG THERAPY FOR CELIAC SPRUE
  申请人：Khosla Chaitan

  公开号：US20080044401A1

  公开（公告）日：2008-02-21

  Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.

  给予具有效剂量的tTGase抑制剂给予患有乳糜泻或疱疹样皮肤炎的患者，可以减少毒性麸质寡肽的毒性影响，从而减轻或消除麸质的有害影响。
• Drug Therapy for Celiac Sprue
  申请人：Khosla Chaitan

  公开号：US20080233102A1

  公开（公告）日：2008-09-25

  Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.

  给予具有有效剂量的tTGase抑制剂给一个乳糜泻或疱疹性荨麻疹患者，可以减轻毒性麸质寡肽的毒性效应，从而减轻或消除麸质的损害作用。